Nikki Carter

Nikki Carter has a diverse work experience spanning multiple industries and roles. Nikki is currently working as the Commercial Organoid Innovation Director at Molecular Devices since April 2023. Prior to that, they worked at Cytiva as the Director of Strategy Search and Evaluation from December 2021 to April 2023. Before that, they held the position of Director of R&D and Laboratories at Excalibur Healthcare Services Ltd from February 2021 to November 2021.

Nikki also has experience working at AstraZeneca in various roles. Nikki served as the Associate Director of Discovery Biology Cellular Assay Development from November 2018 to July 2020, where they demonstrated leadership in cellular assay development and provided strategic and budgetary leadership for new business capabilities. Prior to that, they were the Lead of Global Cell Bank from May 2017 to November 2018.

Before joining AstraZeneca, Nikki worked as a Team Leader in Biology at Charles River Laboratories from November 2016 to May 2017. In this role, they led a small team of scientists and coordinated with clients to deliver contract research projects.

Earlier in their career, Nikki held the position of Senior Scientist at AstraZeneca from August 2012 to November 2016. Nikki gained expertise in screening and assay development and played a key role in driving drug discovery.

Nikki's work experience also includes a role as a Stem Cell Biologist at GE Healthcare from August 2011 to August 2012, and as a Scientist at Pfizer from April 2004 to April 2011.

Overall, Nikki Carter's work experience showcases their expertise in various aspects of the life sciences industry, including business strategy, drug discovery, cellular assay development, and laboratory management.

Nikki Carter began their education in 2000 at the University of Kent, where they pursued a Bachelor of Science degree in Cellular and Molecular Biology. Nikki successfully completed their degree in 2003 with a classification of 2.1. Following their undergraduate studies, from 2008 to 2011, they enrolled in the British Pharmacological Society to obtain a Diploma in Advanced Pharmacology, focusing specifically on the field of Pharmacology.